Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score
The Up7-ALBI score, incorporating tumor burden and liver function, effectively stratified survival outcomes in HCC patients treated with lenvatinib. Further validation in larger cohorts and across different systemic therapies is required to confirm its broad clinical applicability.
Authors
- Yao‐Yu Hsieh (ORCID: https://orcid.org/0000-0003-4368-4281)
- Chien‐Wei Su (ORCID: https://orcid.org/0000-0003-3889-7004)
- Wei‐Yu Kao (ORCID: https://orcid.org/0000-0002-5506-4293)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Kai-I Chuang (ORCID: https://orcid.org/0000-0002-8020-7970)
- Ming‐Shun Wu (ORCID: https://orcid.org/0000-0002-5755-9062)
- Cheng-Fu Ni
- Chih‐Horng Wu (ORCID: https://orcid.org/0000-0002-7498-4183)
- Chien-Hung Lu
- Chia‐Hui Lu (ORCID: https://orcid.org/0000-0003-4143-2136)
- Wei-Yi Ting
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Medical University Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Taiwan University Hospital (TW)
- Wan Fang Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1159/000546185
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Taipei Medical University
- Taiwan Clinical Oncology Research Foundation
- Taipei Veterans General Hospital